...
search icon
xncr-img

Xencor Inc, Common Stock

XNCR

NMQ

$8.06

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$624.17M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
728.90K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.99
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$7.16 L
$27.24 H
$8.06

About Xencor Inc, Common Stock

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameXNCRSectorS&P500
1-Week Return-8.1%-2.11%1.93%
1-Month Return-23.96%0.39%15.64%
3-Month Return-50.25%-9.09%-3.09%
6-Month Return-65.89%-5.75%0.66%
1-Year Return-66.06%-8.84%12.13%
3-Year Return-64.93%3.8%52.62%
5-Year Return-74.2%33.05%103.43%
10-Year Return-51.88%77.34%179.8%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue122.69M275.11M164.58M168.34M110.49M[{"date":"2020-12-31","value":44.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.82,"profit":true},{"date":"2023-12-31","value":61.19,"profit":true},{"date":"2024-12-31","value":40.16,"profit":true}]
Cost of Revenue169.80M7.49M8.80M253.60M253.60M[{"date":"2020-12-31","value":66.96,"profit":true},{"date":"2021-12-31","value":2.95,"profit":true},{"date":"2022-12-31","value":3.47,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit122.69M275.11M164.58M(85.26M)98.39M[{"date":"2020-12-31","value":44.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.82,"profit":true},{"date":"2023-12-31","value":-30.99,"profit":false},{"date":"2024-12-31","value":35.76,"profit":true}]
Gross Margin100.00%100.00%100.00%(50.65%)89.04%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-50.65,"profit":false},{"date":"2024-12-31","value":89.04,"profit":true}]
Operating Expenses199.49M231.34M247.05M306.98M288.90M[{"date":"2020-12-31","value":64.99,"profit":true},{"date":"2021-12-31","value":75.36,"profit":true},{"date":"2022-12-31","value":80.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":94.11,"profit":true}]
Operating Income(76.80M)43.77M(82.47M)(138.64M)(178.41M)[{"date":"2020-12-31","value":-175.47,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-188.44,"profit":false},{"date":"2023-12-31","value":-316.77,"profit":false},{"date":"2024-12-31","value":-407.63,"profit":false}]
Total Non-Operating Income/Expense14.73M39.71M32.78M31.94M(61.23M)[{"date":"2020-12-31","value":37.09,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":82.55,"profit":true},{"date":"2023-12-31","value":80.43,"profit":true},{"date":"2024-12-31","value":-154.18,"profit":false}]
Pre-Tax Income(69.33M)82.63M(54.51M)(120.44M)(234.92M)[{"date":"2020-12-31","value":-83.91,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-65.97,"profit":false},{"date":"2023-12-31","value":-145.76,"profit":false},{"date":"2024-12-31","value":-284.3,"profit":false}]
Income Taxes(5.79M)(7.49M)673.00K5.81M1.62M[{"date":"2020-12-31","value":-99.71,"profit":false},{"date":"2021-12-31","value":-128.91,"profit":false},{"date":"2022-12-31","value":11.58,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":27.83,"profit":true}]
Income After Taxes(63.54M)90.12M(55.18M)(126.25M)(236.54M)[{"date":"2020-12-31","value":-70.5,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-61.23,"profit":false},{"date":"2023-12-31","value":-140.09,"profit":false},{"date":"2024-12-31","value":-262.47,"profit":false}]
Income From Continuous Operations(69.33M)82.63M(55.18M)(119.03M)(236.54M)[{"date":"2020-12-31","value":-83.91,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-66.78,"profit":false},{"date":"2023-12-31","value":-144.05,"profit":false},{"date":"2024-12-31","value":-286.26,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(63.54M)82.63M(55.18M)(126.09M)(232.62M)[{"date":"2020-12-31","value":-76.89,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-66.78,"profit":false},{"date":"2023-12-31","value":-152.59,"profit":false},{"date":"2024-12-31","value":-281.51,"profit":false}]
EPS (Diluted)(1.21)1.35(0.93)(2.10)(3.51)[{"date":"2020-12-31","value":-89.63,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-68.89,"profit":false},{"date":"2023-12-31","value":-155.56,"profit":false},{"date":"2024-12-31","value":-260,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

XNCR
Cash Ratio 5.31
Current Ratio 5.89

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

XNCR
ROA (LTM) -11.42%
ROE (LTM) -34.05%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

XNCR
Debt Ratio Lower is generally better. Negative is bad. 0.29
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.71

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

XNCR
Trailing PE NM
Forward PE NM
P/S (TTM) 4.51
P/B 0.90
Price/FCF NM
EV/R 1.35
EV/Ebitda NM
PEG NM

FAQs

What is Xencor Inc share price today?

Xencor Inc (XNCR) share price today is $8.06

Can Indians buy Xencor Inc shares?

Yes, Indians can buy shares of Xencor Inc (XNCR) on Vested. To buy Xencor Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in XNCR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Xencor Inc be purchased?

Yes, you can purchase fractional shares of Xencor Inc (XNCR) via the Vested app. You can start investing in Xencor Inc (XNCR) with a minimum investment of $1.

How to invest in Xencor Inc shares from India?

You can invest in shares of Xencor Inc (XNCR) via Vested in three simple steps:

  • Click on Sign Up or Invest in XNCR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Xencor Inc shares
What is Xencor Inc 52-week high and low stock price?

The 52-week high price of Xencor Inc (XNCR) is $27.24. The 52-week low price of Xencor Inc (XNCR) is $7.16.

What is Xencor Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Xencor Inc (XNCR) is 0.90

What is the Market Cap of Xencor Inc?

The market capitalization of Xencor Inc (XNCR) is $624.17M

What is Xencor Inc’s stock symbol?

The stock symbol (or ticker) of Xencor Inc is XNCR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top